Targeting inflammasomes: A possible therapeutic approach for periodontal disease (Review)
Authors:
Open Access
- 17 August 2021
- journal article
- Published by Spandidos Publications in World Academy of Sciences Journal
- Vol. 3 (5) , 1-7
Abstract
Inflammasomes are cytosolic multimeric protein complexes that typically comprise a sensor, an adaptor and the zymogen, procaspase‑1. Inflammasomes are a central hub for signaling and the regulation of innate immunity. An inflammasome assembles in response to a diverse range of pathogen‑associated molecular patterns or danger‑associated molecular patterns. Inflammasomes further induce the maturation of interleukin (IL)‑1β and 18 through the proteolytic cleavage of pro‑IL‑1β and pro‑IL‑18. A number of previous studies have highlighted the importance of the appropriate activation of the inflammasome in homeostasis and in the pathogenesis of periodontal disease. Inflammasomes function as a homeostatic checkpoint to regulate the extent of inflammation in health and disease. Thus, further research is required to uncover the modulators and regulators of the inflammasome assembly. The enhanced knowledge of various strategies which may be used to regulate an excessive inflammatory response at the cellular and molecular level may lead to the development of more effective strategies for the treatment and prevention of periodontal disease, as well as its associated systemic diseases.Keywords
This publication has 49 references indexed in Scilit:
- Regulation of inflammasome signalingNature Immunology, 2012
- Inflammasomes in health and diseaseNature, 2012
- Tripartite-Motif Protein 30 Negatively Regulates NLRP3 Inflammasome Activation by Modulating Reactive Oxygen Species ProductionThe Journal of Immunology, 2010
- Expression and regulation of the NALP3 inflammasome complex in periodontal diseasesClinical and Experimental Immunology, 2009
- (S)-1-((S)-2-{[1-(4-Amino-3-chloro-phenyl)-methanoyl]-amino}-3,3-dimethyl-butanoyl)-pyrrolidine-2-carboxylic acid ((2 R,3 S)-2-ethoxy-5-oxo-tetrahydro-furan-3-yl)-amide (VX-765), an Orally Available Selective Interleukin (IL)-Converting Enzyme/Caspase-1 Inhibitor, Exhibits Potent Anti-Inflammatory Activities by Inhibiting the Release of IL-1β and IL-18The Journal of Pharmacology and Experimental Therapeutics, 2007
- Local and systemic total antioxidant capacity in periodontitis and healthJournal of Clinical Periodontology, 2004
- Interleukin‐1β and interleukin‐18: regulation and activity in local inflammationPeriodontology 2000, 2004
- Effects of scaling and root planing on the amounts of interleukin‐1 and interleukin‐1 receptor antagonist and the mRNA expression of interleukin‐1β in gingival crevicular fluid and gingival tissuesJournal of Periodontal Research, 2004
- The interleukin‐1 genotype as a severity factor in adult periodontal diseaseJournal of Clinical Periodontology, 1997
- Bioassay of interleukin 1 (IL-1) in human gingival crevicular fluid during experimental gingivitisArchives of Oral Biology, 1992